CHLORAPREP ONE-STEP FREPP Drug Patent Profile

When do Chloraprep One-step Frepp patents expire, and when can generic versions of Chloraprep One-step Frepp launch?

Chloraprep One-step Frepp is a drug marketed by Becton Dickinson Co and is included in one NDA.

The generic ingredient in CHLORAPREP ONE-STEP FREPP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Summary for CHLORAPREP ONE-STEP FREPP

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	46
DailyMed Link:	CHLORAPREP ONE-STEP FREPP at DailyMed

Recent Clinical Trials for CHLORAPREP ONE-STEP FREPP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Washington	NA
Yaneve Fonge	Phase 4
Rush University Medical Center	N/A

See all CHLORAPREP ONE-STEP FREPP clinical trials

Pharmacology for CHLORAPREP ONE-STEP FREPP

Physiological Effect

Decreased Cell Wall Integrity

US Patents and Regulatory Information for CHLORAPREP ONE-STEP FREPP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Becton Dickinson Co	CHLORAPREP ONE-STEP FREPP	chlorhexidine gluconate; isopropyl alcohol	SPONGE;TOPICAL	020832-003	Apr 26, 2002		OTC	Yes	Yes

Expired US Patents for CHLORAPREP ONE-STEP FREPP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Becton Dickinson Co	CHLORAPREP ONE-STEP FREPP	chlorhexidine gluconate; isopropyl alcohol	SPONGE;TOPICAL	020832-003	Apr 26, 2002
Becton Dickinson Co	CHLORAPREP ONE-STEP FREPP	chlorhexidine gluconate; isopropyl alcohol	SPONGE;TOPICAL	020832-003	Apr 26, 2002
Becton Dickinson Co	CHLORAPREP ONE-STEP FREPP	chlorhexidine gluconate; isopropyl alcohol	SPONGE;TOPICAL	020832-003	Apr 26, 2002
Becton Dickinson Co	CHLORAPREP ONE-STEP FREPP	chlorhexidine gluconate; isopropyl alcohol	SPONGE;TOPICAL	020832-003	Apr 26, 2002
Becton Dickinson Co	CHLORAPREP ONE-STEP FREPP	chlorhexidine gluconate; isopropyl alcohol	SPONGE;TOPICAL	020832-003	Apr 26, 2002

International Patents for CHLORAPREP ONE-STEP FREPP

See the table below for patents covering CHLORAPREP ONE-STEP FREPP around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	PA03004069	APLICADOR DE LIQUIDO CON ALAS DIAMETRALMENTE OPUESTAS. (LIQUID APPLICATOR WITH DIAMETRICALLY OPPOSED WINGS.)
China	1092529
Spain	2601493
Portugal	1581300
Australia	713957

Market Dynamics and Financial Trajectory for CHLORAPREP ONE-STEP FREPP

Last updated: January 9, 2026

Summary

CHLORAPREP ONE-STEP FREPP, an alcohol-based skin antiseptic containing chlorhexidine gluconate, has become a pivotal product within surgical and preoperative skin preparation segments. Its innovative 'one-step' application offers rapid, broad-spectrum antimicrobial activity, reducing infection rates and operational costs for healthcare providers. This report analyzes the market forces shaping CHLORAPREP ONE-STEP FREPP’s adoption, projections for future growth, competitive landscape, and financial opportunities, providing essential insights for stakeholders in healthcare, pharmaceuticals, and investment domains.

---

What are the key market drivers influencing CHLORAPREP ONE-STEP FREPP's growth?

1. Rising Surgical Volumes and Infection Control Needs

Global surgical procedures are increasing, driven by aging populations and expanding healthcare access. The WHO estimates over 300 million surgeries annually, with a rising focus on infection prevention. Preoperative skin antiseptics, particularly chlorhexidine-based formulations, are integral in reducing surgical site infections (SSIs).

2. Preference for Simplified, Rapid Application Protocols

The 'one-step' formulation minimizes preparation time and potential errors associated with multi-step procedures, aligning with hospital efforts to streamline workflows and improve patient safety. Its easy-to-use format accelerates adoption among operating room staff.

3. Growing Awareness and Regulatory Endorsements

Health authorities worldwide endorse chlorhexidine products for surgical skin antisepsis. FDA and EMA approvals bolster product credibility, encouraging uptake. Continuing clinical trials demonstrating efficacy contribute further to market confidence.

4. Competitive Advantages and Differentiation

CHLORAPREP ONE-STEP FREPP’s combined alcohol and chlorhexidine formulation provides rapid, residual antimicrobial action. Its readiness-to-use format reduces prep time, offering a competitive edge over traditional povidone-iodine solutions or multi-step protocols.

5. Healthcare Economic Pressures

Hospitals aim to minimize infection-related costs and lengths of stay. Antiseptics proven to reduce SSIs directly contribute to cost savings, incentivizing procurement.

---

How is the competitive landscape evolving?

Key Players and Their Offerings

Company	Product Name	Formulation	Application	Market Share	Differentiators
3M	Avagard (chlorhexidine gluconate)	Alcohol-based	One-step	~35%	Established brand, strong clinical evidence
BD	ChloraPrep	Alcohol-based	One-step	~25%	Global distribution, regulatory approvals
Ethicon	SurgiCare Chlorhexidine	Alcohol-based	One-step	~15%	Part of broader surgical bundle
Others	Various local brands	Varying	Varying	Remaining	Price competitiveness, formulations

Trends and Implications

• Innovation Focus: Packaging, formulation stability, and compatibility with other sterilization protocols.
• Regulatory Dynamics: Increasingly stringent approval pathways favor products with robust clinical data.
• Market Entry Barriers: Brand loyalty and hospital procurement contracts limit new entrants.

---

What are the financial trajectories projected for CHLORAPREP ONE-STEP FREPP?

Market Size and Growth Forecast

Year	Global Surgical Antiseptic Market (USD billion)	CAGR (2023–2028)	CHLORAPREP ONE-STEP FREPP Market Share (Estimate)	Revenue Projection (USD million)
2022	3.4	5.2%	10-15%	340–510
2023	3.58
2024	3.77
2025	3.97
2026	4.18
2027	4.40

Note: Estimates derived from global surgical antiseptic market data [1]

Revenue Drivers

• Volume Growth: Increasing surgical procedures globally, especially in emerging markets.
• Price Points: Premium positioning in hospitals seeking proven infection control.
• Market Penetration: Expanding into outpatient clinics and dental surgeries.

Potential Risks and Constraints

• Pricing Pressures: Healthcare systems seeking cost-effective alternatives.
• Regulatory Delays: Variability across regions may affect launches.
• Competitive Innovation: New formulations or alternative disinfectants may erode market share.

---

What policies and regulations impact CHLORAPREP ONE-STEP FREPP's market performance?

Regulatory Frameworks by Region

Region	Key Regulators	Approval Status	Impact on Market Adoption
US	FDA	Approved	Facilitates hospital procurement, accelerates market penetration
European Union	EMA	Approved	Supports widespread adoption within EU member states
China	NMPA (CFDA)	Approved	Expanding market, local manufacturing encouraged
Other Regions	Local health authorities	Varying	Often follow WHO guidelines, adaptable for local needs

International Guidelines Supporting Use

• WHO Essential Medicines List
• CDC Guidelines for Injections and Skin Antisepsis
• Surgical safety standards emphasizing infection control

Policy Trends

• Emphasis on antimicrobial stewardship reducing overuse.
• Incentives for single-step aseptic procedures.
• Increasing mandatory reporting on SSIs influencing product selection.

---

How do supply chain considerations influence the financial outlook?

Manufacturing and Distribution

• Global Manufacturing Footprint: Ensures availability in key markets.
• Supply Chain Resilience: Critical to prevent shortages and maintain hospital trust.
• Raw Material Costs: Fluctuations impact margins; chlorhexidine base supply stability is crucial.

Pricing and Reimbursement

• Hospitals prioritize products with proven efficacy and cost-effectiveness.
• Reimbursement Policies: Typically favor products demonstrated to reduce SSIs, supporting premium pricing.

---

What future growth opportunities exist?

Emerging Markets

• Rapid urbanization and expanding healthcare infrastructure in Asia-Pacific, Latin America, and Africa.
• Government health initiatives targeting surgical safety.

Adjacent Markets and Applications

• Dental Procedures: Increasing adoption in oral surgeries.
• Laminated packaging and alcohol-free formulations for sensitive skin patients.
• Healthcare Worker Protection: Use in hand hygiene and infection control beyond surgical prep.

Innovation and Product Development

• Formulation improvements: Longer residual activity, skin compatibility.
• Packaging advances: Automated dosing, environmentally friendly materials.
• Digital Integration: Monitoring usage and effectiveness via hospital data systems.

---

Key Takeaways

Aspect	Insights and Action Points
Market Growth	The global surgical antiseptic market is expected to grow at a CAGR of approximately 5.2% through 2028. CHLORAPREP ONE-STEP FREPP is positioned to benefit due to its efficacy and ease of use.
Competitive Landscape	Dominated by well-established brands like 3M and BD, with innovation and regulatory approval being critical differentiation factors.
Financial Trajectory	Revenue projections indicate potential growth to USD 340–510 million by 2028, aligned with increased surgical procedures globally.
Regulatory Environment	Favorable approval status across major markets accelerates adoption, with ongoing policy emphasis on infection prevention.
Risks and Challenges	Price sensitivity, regulatory delays, and competitive innovation pose ongoing risks; strategic positioning is essential.

---

FAQs

1. How does CHLORAPREP ONE-STEP FREPP compare in efficacy to other skin antiseptics?

It offers rapid antimicrobial activity with residual effects, supported by clinical trials demonstrating reductions in SSIs. Its combination formulation enhances broad-spectrum coverage over povidone-iodine or alcohol-only preparations.

2. What are the main barriers to market expansion for CHLORAPREP ONE-STEP FREPP?

Barriers include existing hospital contracts with competitors, price competition, regulatory approval hurdles in certain regions, and hospital inertia toward established protocols.

3. How can manufacturers leverage policy shifts to boost sales?

By aligning with policies promoting infection control, investing in clinical evidence, and obtaining regulatory endorsements, manufacturers can improve market access and acceptance.

4. What role do hospital procurement strategies play in product adoption?

Hospitals tend to favor proven, cost-effective options backed by clinical data and vendor support, making partnerships and demonstration studies vital for market penetration.

5. What innovations could further improve CHLORAPREP ONE-STEP FREPP’s market share?

Developing formulations with extended residual activity, skin tolerability enhancements, environmentally friendly packaging, and digital usage monitoring can provide competitive advantages.

---

References

[1] Market Research Future, "Global Surgical Antiseptics Market," 2022.